B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New 'Sandwich' strategy aims to boost leukemia survival without donor transplant
Disease control Recruiting nowThis study tests a new treatment plan for adults with B-cell acute lymphoblastic leukemia (B-ALL) who cannot or choose not to have a donor stem cell transplant. The approach uses the drug blinatumomab before and after an autologous (self-donated) stem cell transplant to try to cl…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated May 26, 2026 06:00 UTC
-
Double immune attack: new hope for kids with tough leukemia
Disease control Recruiting nowThis study tests a new approach for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. It combines two types of specially engineered immune cells (CAR T cells) that target different markers on cancer cells.…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated May 26, 2026 05:55 UTC
-
New drug cocktail targets hard-to-treat leukemias in early trial
Disease control Recruiting nowThis early-phase study tests a new drug (ABL001) combined with three existing medicines (dasatinib, prednisone, and blinatumomab) for people with BCR-ABL positive B-cell acute lymphoblastic leukemia or chronic myeloid leukemia in lymphoid blast crisis. The main goal is to find th…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Marlise Luskin, MD • Aim: Disease control
Last updated May 26, 2026 05:49 UTC
-
New combo therapy aims to supercharge Cancer-Fighting cells in tough leukemia cases
Disease control Recruiting nowThis study tests whether adding cytokine-induced killer (CIK) cells can prevent CAR-T cells from wearing out too early in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia. Participants will be randomly assigned to receive either standard c…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 26, 2026 05:49 UTC
-
New CAR-T therapy offers hope for kids with Tough-to-Treat leukemia and lymphoma
Disease control Recruiting nowThis study tests a new type of CAR-T cell therapy for children and teens with B-cell acute lymphoblastic leukemia (B-ALL) or B-cell non-Hodgkin lymphoma (B-NHL) that has come back or not responded to standard treatments. The therapy uses the patient's own immune cells, modified t…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated May 26, 2026 05:48 UTC
-
Ready-made immune cells take on aggressive blood cancers in early trial
Disease control Recruiting nowThis early-phase study tests azer-cel, a pre-made (allogeneic) CAR T cell therapy, in adults with relapsed or refractory non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, and related blood cancers. The goal is to check safety and see if these donor-derived cells can shri…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Imugene Limited • Aim: Disease control
Last updated May 26, 2026 05:48 UTC
-
New hope for kids with relapsed leukemia: donor immune cells enter trial
Disease control Recruiting nowThis early-stage trial tests a new treatment for children and young adults with B-cell acute lymphoblastic leukemia that has come back or not responded to standard therapy. Doctors take immune cells from a healthy donor, modify them to recognize and attack leukemia cells, and giv…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Bambino Gesù Hospital and Research Institute • Aim: Disease control
Last updated May 26, 2026 05:47 UTC
-
Gene therapy breakthrough targets Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage study tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have returned or not improved with standard treatments. The therapy uses a harmless virus to deliver a gene that helps the immune system attack c…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated May 26, 2026 05:46 UTC
-
New hope for leukemia patients: experimental drug YK012 enters human trials
Disease control Recruiting nowThis study tests a new drug, YK012, in 46 people with B-cell acute lymphoblastic leukemia (B-ALL), a type of blood cancer. The main goals are to check the drug's safety, find the best dose, and see if it can shrink or control the cancer. Participants must have CD19-positive B-ALL…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated May 26, 2026 05:45 UTC
-
New cell therapy takes on stubborn leukemia in early trial
Disease control Recruiting nowThis early study tests a new treatment called SYNCAR-100 in 16 adults with a type of blood cancer (B-ALL) that has come back or not responded to standard therapy. The treatment is given once a week for four weeks. The main goal is to check safety and side effects, and also to see…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: EARLY_PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated May 26, 2026 04:38 UTC
-
New CAR T-Cell combo shows promise against tough leukemia
Disease control Recruiting nowThis study tests two different CAR T-cell therapy approaches for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. One group gets a combination of two types of CAR T-cells (CD19 and CD22), while the other gets one type (CD19) follow…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Second-Chance cell therapy: study tests Off-Spec cancer treatment
Disease control Recruiting nowThis study is for people with B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma whose manufactured cell therapy (tisagenlecleucel) didn't meet commercial release standards. The goal is to check if this slightly off-spec product is still safe and effective. Abou…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New drug cocktail IoVeX aims to tame relapsed blood cancer
Disease control Recruiting nowThis early-phase trial tests whether a combination of three drugs—inotuzumab ozogamicin, venetoclax, and dexamethasone (IoVeX)—is safe for people with relapsed B-cell acute lymphoblastic leukemia (B-ALL). About 28 children and adults will receive the drugs over one or two 28-day …
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New CAR-T therapy targets tough blood cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a new treatment called CLIC-2201 for people with certain blood cancers (like lymphoma or leukemia) that have not responded to standard therapy or have returned. The treatment uses a patient's own immune cells, which are modified in a lab to better rec…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Donor immune cells target hard-to-treat leukemia in new safety trial
Disease control Recruiting nowThis study tests a two-step treatment for people with a type of leukemia that has come back or not responded to standard care. First, participants receive donor immune cells (CAR T cells) that target a protein called CD19 on cancer cells, followed by a stem cell transplant from t…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New dual-target CAR t therapy offers hope for kids with relapsed leukemia
Disease control Recruiting nowThis study tests a new type of cell therapy (CD19x22 CAR T) in children whose B-cell acute lymphoblastic leukemia has come back or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to attack two targets on leukemia cells. The main goa…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
Personalized chemo boosts CAR T-Cell success in childhood leukemia trial
Disease control Recruiting nowThis study tests whether giving a personalized dose of the chemotherapy drug fludarabine before CAR T-cell therapy can improve outcomes for children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia. About 130 participants will be randomly assign…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 18, 2026 12:11 UTC
-
New drug trial offers hope for young cancer patients
Disease control Recruiting nowThis study tests a new drug called zilovertamab vedotin in children and young adults (up to age 30) whose blood cancers or solid tumors have come back or not responded to treatment. The goal is to see if the drug is safe and can shrink or control the cancer. About 90 participants…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 18, 2026 12:09 UTC
-
Engineered donor cells take on tough leukemia in early trial
Disease control Recruiting nowThis study tests a new treatment called UCART22 for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or not responded to standard therapies. UCART22 uses donor immune cells that are engineered to recognize and attack cancer cells carryin…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Cellectis S.A. • Aim: Disease control
Last updated May 18, 2026 12:01 UTC
-
New hope for older leukemia patients: easier treatment combo enters trial
Disease control Recruiting nowThis study tests a new way to treat B-cell acute lymphoblastic leukemia (B-ALL) in people aged 60 and older, or younger adults who cannot handle strong chemotherapy. The treatment combines a drug called blinatumomab, given as a shot under the skin, with a milder chemotherapy. The…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
Leukemia treatment may erase vaccine immunity – study seeks answers
Knowledge-focused Recruiting nowThis study looks at whether children and young adults (up to age 21) treated for B-cell acute lymphoblastic leukemia with the drug blinatumomab still have protection from routine childhood vaccines. Researchers will measure antibody levels for diseases like tetanus, hepatitis B, …
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Sponsor: Arkansas Children's Hospital Research Institute • Aim: Knowledge-focused
Last updated May 26, 2026 06:01 UTC